Galleri Cancer Test Faces Scrutiny Over Early Detection Claims
FDA advisory panel recommends approval despite lack of evidence for reducing cancer mortality.
1New Screening Technology
The Galleri test, developed by biotech firm GRAIL, aims to detect over 50 types of cancer from a single blood draw. It identifies unique DNA methylation markers associated with tumor cells. While it represents a novel approach to screening, its clinical efficacy remains a subject of intense debate among medical professionals.
2FDA Advisory Panel Vote
On September 23, 2026, a U.S. FDA advisory panel voted to recommend the test for approval. However, panelists expressed significant reservations, specifically requesting the removal of the word 'early' from product labeling. This highlights a disconnect between the test's marketing claims and the actual clinical evidence regarding its detection capabilities.
3Detection Rate Shortcomings
Clinical trial data reveals that the Galleri test misses over two-thirds of all cancer cases across various stages. Specifically, the detection rate for early-stage cancers was only 21% over three years of screening. This performance is concerning because early detection is the primary goal for improving survival rates in cancer patients.
4Lack of Mortality Benefit
The most critical limitation is that the test has not yet proven it can reduce the risk of dying from cancer. Clinical trials failed to demonstrate a reduction in the incidence of late-stage cancers over three years. Without such evidence, the long-term clinical value of the test remains unproven for patients.
5High Precision Strengths
The test demonstrates a very low false positive rate of approximately 0.5%, meaning only one in 200 people receive an incorrect cancer identification. Furthermore, it boasts a 52% positive predictive value across three annual screens. It also accurately predicts the organ of origin for detected tumors in 91% of diagnosed cases.
6Comparison to Standard Screenings
Currently recommended screenings, such as mammography or colonoscopies, have established track records for reducing mortality. In contrast, the Galleri test does not perform better than these standard methods at detecting early-stage disease. Experts emphasize that patients should prioritize proven screenings for breast, colon, cervical, and lung cancers regardless of blood test results.
7The Risk of False Reassurance
A significant danger of the Galleri test is the potential for false reassurance from a negative result. Because the test misses nearly 80% of early-stage cancers, patients might incorrectly assume they are cancer-free. This could lead to delayed diagnosis and treatment, ultimately undermining the very purpose of undergoing a cancer screening test.
8Financial and Diagnostic Burdens
The test currently costs US$949, and FDA approval does not guarantee insurance coverage from Medicare or Medicaid. Additionally, a positive result necessitates further invasive diagnostic procedures, such as biopsies. These follow-up tests carry their own inherent risks and costs, which can be particularly burdensome if the initial blood test result is a false alarm.
9Panelist Skepticism and Hope
During the FDA advisory process, some panelists admitted their 'yes' votes were based on hope rather than concrete evidence. They acknowledged the test's serious limitations but favored broader access to new screening technology. This subjective optimism contrasts sharply with the rigorous data requirements typically expected for medical diagnostic approval and patient safety.
10Informed Decision Making
Patients considering the Galleri test should consult their physicians to weigh the costs against the current lack of mortality benefit. While the technology is promising, it is not yet a universal breakthrough. Maintaining adherence to established, evidence-based screening guidelines remains the most effective strategy for managing cancer risk and improving health outcomes.